Related Experiment Video

Updated: Dec 27, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.7K

Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor

Ishac Nazy1,2, Taylor D Elliott1,3, Donald M Arnold1,2,4

  • 1Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

British Journal of Haematology
|March 5, 2020
PubMed

Insights

Platelet factor 4 (PF4) binds von Willebrand factor (VWF), inhibiting its breakdown by ADAMTS13. VWF-PF4 complexes are found in patients with thrombotic thrombocytopenic purpura (TTP), suggesting PF4 regulates VWF during clotting.

Area of Science:

  • Hematology
  • Biochemistry
  • Thrombosis Research

Background:

  • Von Willebrand factor (VWF) multimeric size is crucial for thrombus formation.
  • ADAMTS13 protease regulates VWF multimeric size, but its activity regulation is unclear.

Purpose of the Study:

  • To investigate if Platelet Factor 4 (PF4) binds VWF.
  • To determine if PF4 inhibits ADAMTS13 activity.
  • To explore the role of VWF-PF4 complexes in thrombotic thrombocytopenic purpura (TTP).

Main Methods:

  • VWF-PF4 binding assays.
  • ADAMTS13 activity assays in the presence of PF4.
  • Detection of VWF-PF4 complexes in patient plasma.

Main Results:

  • PF4 was found to bind VWF.
  • PF4 binding protected VWF from ADAMTS13-mediated cleavage.
  • VWF-PF4 complexes were detected in patients with TTP.

Conclusions:

  • PF4 inhibits ADAMTS13 activity by binding to VWF.
  • VWF-PF4 complexes are present in TTP patients.
  • PF4 may play a novel role in regulating VWF during primary hemostasis and thrombosis.
Keywords:
ADAMTS13platelet factor 4plateletsthrombosisvon Willebrand factor

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.0K
In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

11.1K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
970
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.5K